Previous clinical trials showed that approximately 10% of patients with advanced HR+, HER2-BC receiving the first-line treatment consisting of CDK4/6 inhibitors with ET had less than 6 months of PFS, suggesting primary endocrine resistance (8–10). Here, ERBB2 is linked to breast cancer.